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Abstract: Microorganisms living in extreme environments represent a huge reservoir of novel
antimicrobial compounds and possibly of novel chemical families. Antarctica is one of the most
extraordinary places on Earth and exhibits many distinctive features. Antarctic microorganisms are
well known producers of valuable secondary metabolites. Specifically, several Antarctic strains have
been reported to inhibit opportunistic human pathogens strains belonging to Burkholderia cepacia
complex (Bcc). Herein, we applied a biodiscovery pipeline for the identification of anti-Bcc
compounds. Antarctic sub-sea sediments were collected from the Ross Sea, and used to isolate
25 microorganisms, which were phylogenetically affiliated to three bacterial genera (Psychrobacter,
Arthrobacter, and Pseudomonas) via sequencing and analysis of 16S rRNA genes. They were then
subjected to a primary cell-based screening to determine their bioactivity against Bcc strains. Positive
isolates were used to produce crude extracts from microbial spent culture media, to perform the
secondary screening. Strain Pseudomonas BNT1 was then selected for bioassay-guided purification
employing SPE and HPLC. Finally, LC-MS and NMR structurally resolved the purified bioactive
compounds. With this strategy, we achieved the isolation of three rhamnolipids, two of which were
new, endowed with high (MIC < 1 µg/mL) and unreported antimicrobial activity against Bcc strains.
Keywords: antimicrobials; ramnholipids; Antarctic; Bcc; microorganisms
1. Introduction
The alarming rise of Multi-Drug Resistance (MDR) bacteria in the last few decades has highlighted
the need for novel antimicrobial compounds and for effective drug discovery approaches [1,2]. Natural
products are the largest source of new antibiotic molecules, representing about two-thirds of new
antibacterial therapies approved between 1980 and 2010 [3,4]. Bioprospecting for natural products from
unexplored natural environments, such as the marine environment is considered a promising strategy
to identify novel compounds. It is increasingly recognized that a huge number of natural products and
novel chemical entities exist in these environments, but the overwhelming biological diversity of these
environments has so far only been explored to a very limited extent [5,6]. The Antarctic environment,
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as well as having incredibly low temperatures, possesses other diverse traits that may have helped to
shape the unique way in which Antarctic bacteria have evolved. This extreme environment contains
hyper-salinity that exists in sea ice brine channels, a lack of free water due to freezing temperatures,
as well as low nutrient availability. Unique light conditions also exist due to the high latitude of the
region. Several studies have shown that Antarctic bacteria harvested from Antarctic corals and sponges
are a promising source of new antimicrobial compounds [7–14]. Specifically, several Antarctic strains
belonging to the genus Pseudoalteromonas, Psychrobacter, Pseudomonas, and Arthrobacter, were able to
inhibit the growth of several strains belonging to the Burkholderia cepacia complex (Bcc) [11,14]. Further
studies demonstrated that the antimicrobial activity relies (at least in part) on the production of Volatile
Organic Compounds (VOCs) [12,13,15]. The Bcc consists of at least 20 closely related species inhabiting
different ecological niches such as water, soil, plants rizosphere, and plants and animals [16–18].
Bcc are also opportunistic human pathogens that cause lung infections in immune-compromised
individuals, including cystic fibrosis (CF) patients [19]. In one-third of infected individuals, it causes
the “cepacia syndrome”—a form of septic shock, which involves the lungs essentially shutting down,
resulting in fatality [20–22]. Bcc bacteria have proven to be very resilient and incredibly difficult to
combat as they are resistant to almost all known antimicrobial agents and can survive under the most
extreme conditions [23]. In this publication, we report a complete biodiscovery pipeline aiming at
the identification of novel anti-Bcc compounds, starting from the isolation of bacteria from Antarctic
sub-sea sediments. Bacteria were tested for their antimicrobial potential and a bioassay-guided
purification was performed that yielded three bioactive compounds active against Bcc. Structures were
then elucidated and two compounds have not been reported previously.
2. Results and Discussion
2.1. Isolation of Bacteria, Typing and Phylogenetic Analysis
Psychrophilic Antarctic bacteria were isolated from sediments on PYG minimal medium. After
15 days of incubation at 4 ˝C, 25 visible colonies where picked and grown in liquid PYG at 15 ˝C for
48 h in agitation, and glycerol stab were stored at ´80 ˝C.
In order to check whether the 25 bacterial isolates represented either the same or different
strains, an RAPD analysis was carried out using the primers 1253 (51-GTTTCCGCCC-31) and
AP5 (51-TCACGCTGCG-31). The RAPD profiles obtained were then compared among them; the
comparative analysis obtained with primer 1253 revealed that the 25 Antarctic isolates were split
into 18 different RAPD groups (hereinafter, RAPD haplotypes), most of which were represented by
just one bacterial isolate as summarized in Table 1. Two groups embedding more than one isolate
were identified: group 1 (RAPD halpotype 1) including strains BTN1, BTN6, BTN 7, BTN8, BTN9 and
BTN10 and group 4 (embedding isolates BTN20A, BTN20B, and BTN24). These data were completely
confirmed by the RAPD analysis performed with primer AP5.
The phylogenetic affiliation of bacterial isolates was performed through the 16S rRNA genes
amplification and analysis. For this purpose, the 16S rRNA genes were PCR amplified and the
nucleotide sequence of the amplicons determined. Each sequence was used as a query in a BLAST
search to retrieve the most similar ones. Sequences were then aligned using the program ClustalW and
the alignment was used to construct the phylogenetic trees shown in Figure S1, revealing that:
(i) As expected on the basis of the sharing of RAPD profiles, the six strains exhibiting the same RAPD
profile (RAPD haplotype 1) share the same 16S rRNA gene sequence and were clustered together
joining the species Pseudomonas azotoformans.
(ii) Strain BTN4 was affiliated to the genus Arthrobacter.
(iii) All the other strains were affiliated to the genus Psychrobacter and, according to the different
RAPD profiles they exhibited, joined different Psychrobacter clades. The three strains (BTN20A,
BTN24 and BTN 20B) sharing the same RAPD profile (RAPD haplotype 4), joined the same
Psychrobacter cluster.
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Table 1. List of the strains used in this work; for each strain, the genus and the RAPD haplotype
are reported.
Genus Strains RAPD Profile Accession Number
Pseudomonas
BTN1
1
KT989002
BTN6 KT989003
BTN7 KT989004
BTN8 KT989005
BTN9 KT989006
BTN10 KT989007
Psychrobacter
BTN3 2 KT989009
BTN19 3 KT989019
BTN20B
4
KT989021
BTN24 KT989022
BTN21 5 KT989025
BTN23 6 KT989024
BTN2 7 KT989008
BTN11 8 KT989011
BTN5 9 KT989010
BTN20A 4 KT989020
BTN15 10 KT989015
BTN13 11 KT989012
BTN14 12 KT989013
BTN17 13 KT989017
BTN16 14 KT989016
BTN18 15 KT989018
BTN12 16 KT989014
BTN22 17 KT989023
Arthrobacter BTN4 18 KT989001
2.2. Cross-Streaking Experiments
In order to check the ability of Antarctic bacteria to inhibit the growth of Bcc strains, cross-streaking
experiments were performed using representatives of each RAPD haplotype as test strains. We used as
targets a panel of 84 different Bcc strains belonging to 17 known species (see Table S1). Most of the
strains had a clinical origin. Data obtained are summarized in Table S1, revealing that all BTN strains
are able to completely inhibit the growth of Bcc strains. In order to check whether this anti-Bcc activity
was due to Volatile Organic Compounds (VOCs) synthesis, a further cross-streaking experiment was
performed using Petri dishes with a central septum, which physically separates the tester (Antarctic)
from the target strains. To perform this analysis, we selected the 17 Bcc type strains listed in Table S2,
which are highlighted in red. Data obtained are reported in Table 2 and revealed that the inhibitory
power of the BTN strains decreased in the presence of the central septum. This finding suggested that
BTN strains synthesize a combination of volatile and soluble molecules and that the Bcc-inhibitory
activity likely might rely principally on the soluble fraction. Thus, we decided to concentrate our
efforts on the soluble molecules for this study.
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Table 2. Growth of Bcc strains in cross-streaking experiments carried out using Petri dishes either with (W) or without (N) a central septum (S). Symbols: +, growth; ˘,
reduced growth; -, no growth.
Bcc Strain S
BTN Strain
1 2 3 5 11 13 14 4 12 15 16 17 18 19 20 a 20 b 21 22 23 C+
B. ambifaria LMG 19182 W - - - - - - - - - - - - - - - - - - - +
N - - - - - - - - - - - - - - - - - - - +
B. anthina LMG 20980
W - - - - - - - - - - - - - - - - - - - +
N - - - - - - - - - - - - - - - - - - - +
B. vietnamensis LMG10929
W - - - - - - - - - - - - - - - ˘ - - - +
N - - - - - - - - - - - - - - - - - - - +
B. cenocepacia LMG 16656 W ˘ - ˘ ˘ - ˘ - - - - - ˘ ˘ - ˘ ˘ - - - +
N - - - - - - - - - - - - - - - - - - - +
B. cepacia LMG 1222 W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. contaminas LMG 23361
W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. diffusa LMG 24065 W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. dolosa LMG 18943
W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. lata LMG 22485
W ˘ ˘ ˘ ˘ ˘ ˘ ˘ - ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. latens LMG 24064
W - - ˘ ˘ ˘ - - - - ˘ ˘ ˘ ˘ - ˘ ˘ - - ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. metallica LMG 24068
W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. multivorans LMG 13010
W - ˘ ˘ ˘ ˘ ˘ ˘ - ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
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Table 2. Cont.
Bcc Strain S
BTN Strain
1 2 3 5 11 13 14 4 12 15 16 17 18 19 20 a 20 b 21 22 23 C+
B. pseudomultivorans LMG 26883 W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. pyrrocinia LMG 14191 W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. seminalis LMG 24067
W - ˘ ˘ ˘ ˘ ˘ ˘ - ˘ - ˘ ˘ ˘ ˘ ˘ - ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. stabilis LMG 14294
W ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ ˘ - ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
B. uborrensis LMG 20358
W - - ˘ ˘ ˘ ˘ ˘ - ˘ ˘ ˘ ˘ ˘ - ˘ ˘ ˘ ˘ ˘ +
N - - - - - - - - - - - - - - - - - - - +
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2.3. Extracts’ Antimicrobial Assays
Eight of the most active Antarctic strains belonging to the three different genera (Pseudomonas,
Psychrobacter, and Arthrobacter) were selected and used to produce extracts, which were then tested
against a reduced panel of Bcc type-strains isolated from CF patients. The MIC assays were carried out
as described in Materials and Methods. Table 3 reports the antimicrobial activity as percentage of Bcc
growth inhibition in the presence of each extract at a concentration of 1 mg/mL.
Table 3. Antimicrobial activity of BTN cell extracts reported as % of inhibition of Bcc strains treated
with 1 mg/mL of BTN extracts.
Pseudomonas Psychrobacter Arthrobacter
Species Strain BTN 1 BTN 2 BTN 15 BTN 3 BTN 19 BTN 21 BTN 5 BTN 4
B. diffusa LMG24065 100 ˘ 0 75 ˘ 3 77 ˘ 3 43 ˘ 7 45 ˘ 11 70 ˘ 4 77 ˘ 9 63 ˘ 3
B. metallica LMG24068 92 ˘ 4 70 ˘ 5 71 ˘ 3 32 ˘ 2 30 ˘ 3 53 ˘ 5 77 ˘ 4 64 ˘ 9
B. cenocepacia LMG16656 100 ˘ 0 78 ˘ 2 87 ˘ 1 84 ˘ 6 64 ˘ 4 45 ˘ 1 84 ˘ 2 57 ˘ 1
B. latens LMG24064 100 ˘ 0 53 ˘ 11 75 ˘ 2 55 ˘ 6 43 ˘ 3 65 ˘ 2 56 ˘ 3 41 ˘ 2
B. seminalis LMG24067 100 ˘ 0 43 ˘ 6 67 ˘ 5 73 ˘ 8 45 ˘ 6 78 ˘ 11 40 ˘ 3 56 ˘ 3
Data obtained revealed that the extracts were differentially active against the selected Bcc strains.
Three Antarctic bacterial strains, i.e., BTN2, BTN15, and BTN5, were able to inhibit at least three of
the five Bcc strains more than 70% of growth. However, the extract from Pseudomonas BTN1 exhibited
the best anti-Bcc activity; indeed, it was able to almost completely inhibit the growth of all the target
strains at the concentration used. For this reason, this strain was selected for further scale-up and
extract purification.
2.4. Bioassay-Guided Purification of BTN1 Extract
Pseudomonas sp. BTN1 strain was grown in 3 L TYP medium for five days at 20 ˝C; then, the culture
broth was extracted with ethyl acetate. Subsequently, the crude extract (1 g) was fractionated with
an SPE C18 Cartridge. Elution was performed stepwise with an increasing methanol concentration.
The four eluted fractions were collected, dried and dissolved in DMSO to perform bioassay at a
stock concentration of 50 mg/mL. The fraction eluted at 100% methanol was shown to be the most
active one against B. cenocepacia LMG 16656 with a MIC of 50 µg/mL and was subjected to HPLC
separation. HPLC chromatograms extracted from 200 to 400 nm presented 11 different peaks, which
were separated, dried and dissolved in DMSO at a stock concentration of 10 mg/mL to perform MIC
assay. Data obtained revealed promising inhibitory activity against B. cenocepacia strain LMG 16656 of
three compounds, hereinafter referred to as Compound 1, 2 and 3, respectively.
2.5. Compound Structure Elucidation
Compounds structures are shown in Figure 1. The molecular formula of compound 1 was
established as C28H52O9 by HRESIMS (555.3514 ∆ 0.92 ppm [M + Na]+. Dereplication of this
compound based on 1D, 2D NMR and LC-MS data indicated that it is a known rhamnolipid [24]
containing two fully saturated lipid chains. The chain lengths of lipids A and B of compound 1
contained 10 and 12 carbons respectively were confirmed by analysis of MS/MS fragmentation data
(Figure S19). The molecular formula of compound 2 was established as C28H50O9 by high-resolution
electrospray ionization mass spectrometry (HRESIMS) (553.3343 ∆ ´0.75 ppm [M + Na]+) and
subsequent dereplication suggested it was new. The molecular formula suggested four degrees
of unsaturation.
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Figure 1. Structures of the three rhamnolipids isolated from Pseudomonas BTN1. 
The 1H, 13C-NMR data (Table 1) in CD3OD of 2 revealed one ester (δC 173.4 ppm), one carboxylic 
acid group (δC 171.40) ppm, two olefinic carbons (δC 132.8, 123.7 ppm), and an anomeric carbon (δC 
98.47 ppm) of a sugar unit. This analysis accounted for three of the double bond equivalents, 
suggesting that the sugar unit was present as a ring. The structure of compound 2 was elucidated 
based on 2D NMR correlation experiments. Data clearly showed three distinctive spin systems. 
There were COSY correlations observed between the anomeric proton and the adjacent protons of 
the sugar unit. There was a strong observed COSY correlation between the methyl group at δH 1.27 
ppm and the proton at δH 3.38 ppm placing the methyl group at position C5. The proposed structure 
was fully supported by COSY and HMBC correlations (Table 4 and Figure S10) indicating that 
compound 2 is a rhamnolipid with the A and B chains having 10 and 12 carbons respectively, and a 
single unsaturation at position B5. Further evidence supporting the structure came from careful 
interpretation of MS/MS fragmentation data (Figure S21). The relative orientation of the rhamnose 
moiety in compound 2 was identified as α based on detailed analysis of ROE data (2D ROESY), 
chemical shifts and proton coupling constants [24,25]. Analysis of ROESY data showed an ROE 
correlation between H-1 and H-2 suggesting that both occupied equatorial positions. This is in 
agreement with the observed small coupling constant 3J(1,2) of about 1.4 Hz in CD3OD and a broad 
singlet in DMSO-D6. A ROE correlation between H-3 and H-5 suggested that both were in axial 
positions (Figure S13). In addition, ROE correlations were observed between H-3 and H-2 
(axial-equatorial), H-6 and H-5 (equatorial-axial) and between H-6 and H-4 (equatorial-axial). This 
conformation is in agreement with observed coupling constants: 3J(2,3, 3.5 Hz), 3J(3,5, 9.5 Hz) and 
3J(4,5, 9.8 Hz). All the data is consistent with the rhamnose unit oriented in a α position. A 2D ROESY 
NMR spectrum is available in the supporting information (Figure S12). 
The molecular formula of compound 3 was established as C30H54O9 by HRESIMS 581.3649 Δ 
1.72 ppm [M + Na]+. Based on 1D, 2D NMR and LC-MS data compound 3 was similar to 2, the 
difference being an additional C2H4 unit. However, careful interpretation of the data indicated that 
both the lipid chains A and B were C12 carbons with a single unsaturation at position B7 instead of 
C10 and C12 carbons and an unsaturation position at B5 in 2. Further evidence of this structure came 
from MS/MS fragmentation data (Figure S23). The relative configuration of the rhamnose unit was 
similar to that of compounds 1 and 2 based on similarities of chemical shifts and proton coupling 
constants. In all three compounds, it is assumed that the rhamnose moieties have the normal 
L-configuration. In addition, the absolute stereochemistry of position H-3 in the lipid chains A and B 
have not been determined. 
 
Figure 1. Structures of the three rha nolipids isolated fro Pseudo onas BT 1.
The 1H, 13C-NMR data (Table 1) in CD3OD of 2 revealed one ester (δC 173.4 ppm), one carboxylic
acid group (δC 171.40) ppm, two olefinic carbons (δC 132.8, 123.7 ppm), and an anomeric carbon
(δC 98.47 ppm) of a sugar unit. This analysis accounted for three of the double bond equivalents,
suggesting that the sugar unit was present as a ring. The structure of compound 2 was elucidated
based on 2D NMR correlation experiments. Data clearly showed three distinctive spin systems. There
were COSY correlations observed between the anomeric proton and the adjacent protons of the sugar
unit. There was a strong observed COSY correlation between the methyl group at δH 1.27 ppm and
the proton at δH 3.38 ppm placing the methyl group at position C5. The proposed structure was fully
supported by COSY and HMBC correlations (Table 4 and Figure S10) indicating that compound 2 is a
rhamnolipid with the A and B chains having 10 and 12 carbons respectively, and a single unsaturation
at position B5. Further evidence supporting the structure came from careful interpretation of MS/MS
fragmentation data (Figure S21). The relative orientation of the rhamnose moiety in compound 2
was identified as α based on detailed analysis of ROE data (2D ROESY), chemical shifts and proton
coupling constants [24,25]. Analysis of ROESY data showed an ROE correlation between H-1 and
H-2 suggesting that both occupied equatorial positions. This is in agreement with the observed
small coupling constant 3J(1,2) of about 1.4 Hz in CD3OD and a broad singlet in DMSO-D6. A ROE
correlation between H-3 and H-5 suggested that both were in axial positions (Figure S13). In addition,
ROE correlations were observed between H-3 and H-2 (axial-equatorial), H-6 and H-5 (equatorial-axial)
and between H-6 and H-4 (equatorial-axial). This conformation is in agreement with observed coupling
constants: 3J(2,3, 3.5 Hz), 3J(3,5, 9.5 Hz) and 3J(4,5, 9.8 Hz). All the data is consistent with the rhamnose
unit oriented in a α position. A 2D ROESY NMR spectrum is available in the supporting information
(Figure S12).
The molecular formula of compound 3 was established as C30H54O9 by HRESIMS 581.3649
∆ 1.72 ppm [M + Na]+. Based on 1D, 2D NMR and LC-MS data compound 3 was similar to 2, the
difference being an additional C2H4 unit. However, careful interpretation of the data indicated that
both the lipid chains A and B were C12 carbons with a single unsaturation at position B7 instead
of C10 and C12 carbons and an unsaturation position at B5 in 2. Further evidence of this structure
came from MS/MS fragmentation data (Figure S23). The relative configuration of the rhamnose
unit was similar to that of compounds 1 and 2 based on similarities of chemical shifts and proton
coupling constants. In all three compounds, it is assumed that the rhamnose moieties have the normal
L-configuration. In addition, the absolute stereochemistry of position H-3 in the lipid chains A and B
have not been determined.
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Table 4. NMR data of 2 and 3 in CD3OD. a 150 MHz; b 600 MHz.
2 3
Position ™C/ppm a, m ™H/ppm (m, J in Hz) b COSY 1H–1H HMBC HÑC ™C/ppm a, m ™H/ppm (m, J in Hz) b COSY 1H–1H HMBC HÑC
A 1 173.4, C 175.5, C
2 38.9, CH2 2.58, m A3 A1 40.9, CH2 2.54, m A3 A1
3 71.1, CH 5.27, pentet, 6.4 A2, A3 A1, A2 72.7, CH 5.29, pentet, 6.5 A2, A4 A1, A2
4 33.8, CH2 1.64, m A3 A3 34.9, CH2 1.63, bm A3 A3
5 24.9, CH2 1.35, overlap 26.0, CH2 1.35, overlap
6 29.3, CH2 1.31, overlap 30.5, CH2 1.37, overlap
7 29.3, CH2 1.31, overlap 30.1, CH2 1.32, overlap
8 31. 6, CH2 1.31, overlap 29.8, CH2 1.33, overlap
9 22.3, CH2 1.33, overlap A10 A10 30.2, CH2 1.36, overlap A10 A10
10 13.1, CH3 0.92, m A9 A9 32.7, CH2 1.31, overlap A9 A9
11 23.4, CH2 1.33, overlap
12 14.1, CH3 0.92, m
B 1 171.4, C 172.3, CH
2 39.5, CH2 2.53, m B3 B1 41.0, CH2
A: 2.60, m
B: 2.50, m B3 B1
3 72.9, CH 4.16, pentet, 5.8 B2, B4 B1, B5 74.8, CH 4.10, pentet, 5.9 B2, B4 B1, B5
4 30.4, CH2
A: 2.39, m
B: 2.33, m B3, B5 B3, B5 33.5, CH2 1.58, bm B3,B5 B3, B5
5 123.7, CH 5.40, m B4, B6 B3, B4, B6, B7 25.7, CH2 1.43, overlap B4, B6
6 132.8, CH 5.55, m B5, B7 B5, B8 27.8, CH2 2.08, overlap B5, B7
7 27.1, CH2 2.08, m B6 B5, B6 130.0, CH 5.37, m B6, B8 B8, B6, B9
8 29.3, CH2 1.31, overlap 131.2, CH 5.39, m B7 B7
9 28.9, CH2 1.33, overlap B7 32. 7, CH2 1.31, overlap B8
10 31.6, CH2 1.31, overlap 32.7, CH2 1.31, overlap
11 22.3, CH2 1.33, overlap B12 23.4, CH2 1.33, overlap B12
12 13.1, CH3 0.92, m B11 14.1, CH3 0.92, m B11
C 1 98.5, CH 4.86, overlap C2 B3, C2 100.0, CH 4.80, d, 1.4 C2 B3, C2
2 71.2, CH 3.77, dd, 3.5, 1.4 C1, C3 C3, C4 72.4, CH 3.76, dd, 3.4, 1.4 C1, C3 C3, C4
3 70.9, CH 3.64, dd, 9.5, 3.5 C2, C4 C5 71.9, CH 3.66, dd, 9.7, 3.4 C2, C4 C5
4 72.7, CH 3.38, dd, 9.5, 9.8 C3,C5 C3 73.8, CH 3.35, dd, 9.7, 9.8 C3, C5 C3
5 68.7, CH 3.67, m C4, C6 C4, C6 69.8, CH 3.68, m C4, C6 C4, C6
6 16.6, CH3 1.27, d, 6.2 C5 C5 17.6, CH3 1.27, d, 6.3 C5 C5
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2.6. Antimicrobial Activity of BTN1 Pure Compounds
The three monorhamnolipids isolated from strain BTN1 were tested against a selected panel of
Bcc strains isolated from CF patients and S. aureus. MIC and MBC values are reported in Table 5. It is
worth noticing that the three compounds have identical MIC and MBC values indicating a bactericidal
effect against the target bacteria, as reported for several natural biosurfactants [26,27]. Compounds 2
and 1 were the most active compounds as they were effective against all the tested stains, with the only
exception of B. diffusa. Specifically, compounds 2 and 1 had the lowest MBC values against B. cenocepacia
(3.12 µg/mL) and S. aureus (respectively, 3.12 and 1.56 µg/mL). Compound 3 had antimicrobial effect
only against S. aureus with an MBC value of 100 µg/mL, while it resulted in being ineffective towards
Bcc strains. Rhamnolipids (RLs) are well-known secondary metabolites synthesized by members of
different Gram-negative species, particularly from bacteria belonging to the genus Pseuedomonas. They
perform several potential functions in bacteria: as powerful biosurfactants, they are involved in the
uptake and b tested stains, with the only exception of polymerase and 0.6 iodegradation of poorly
soluble substrates and are essential for surface motility and biofilm development [28]. Recently, they
have emerged as potential antimicrobials against a broad range of pathogens such as Staphylococcus,
Mycobacterium, and Bacillus, and significant activity against a number of Gram-negative species,
including Serratia marcescens, Enterobacter aerogenes, and Klebsiella pneumoniae [29–31]. RLs act like
synthetic surfactants and their proposed mechanism of action consists of intercalation into biological
membranes and destruction by their permeabilizing effect leading to cell death [32].
Table 5. MIC and MBC values of the 3 mono-rhamnolipids isolated in this study.
Antimicrobial Activity (µg/mL)
B. cenocepacia
LMG 16656
B. metallica
LMG 24068
B. seminalis
LMG 24067
B. diffusa
LMG 24065
B. latens LMG
24064
S. aureus
6538P
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
C1 3.12 3.12 50 50 12.5 12.5 >200 >200 12.5 12.5 1.56 1.56
C2 3.12 3.12 25 25 3.12 3.12 200 200 12.5 12.5 3.12 3.12
C3 200 200 >200 >200 >200 >200 >200 >200 >200 >200 100 100
3. Experimental Section
3.1. Isolation of Bacterial Strains
The Antarctic bacterial strains used in this study were isolated from environmental samples
collected at ´20 m of depth (sub-sea sediments) near the Mario Zucchelli Station, Baia Terranova, Ross
sea, Antarctica (74.6936˝ S, 164.1117˝ E). 1 gr of sediments was mixed with 20 mL of M9 salts solution
(KH2PO4 3.0 g/L, Na2HPO46.0 g/L, NaCl 0.5 g/L, NH4Cl 1.0 g/L) in a 50 mL Falcon tube and gently
mixed; the supernatant was serially diluted in sterile M9 buffer and plated on PYG medium (Peptone
5.0 g/L, Yeast extract 4.0 g/L, Glucose 1.0 g/L, CaCl2 0.2 g/L, MgSO4.7H2O 0.4 g/L, K2HPO4 1.0 g/L,
KH2PO4 1.0 g/L, NaHCO310.0 g/L NaCl 2.0 g/L and 17 g/L). After 15 days of incubation, 24 visible
colonies were picked, grown in liquid PYG and stored at ´80 ˝C.
3.2. Target Strains and Growth Conditions
Bcc strains used in this work are listed in Table 2 and Table S1. Bcc and S. aureus 6538P were
routinely grown on Luria-Bertani broth (LB) (Tryptone 10 g/L, Yeast extract 5 g/L, NaCl 10 g/L) at
37 ˝C. BTN isolated Antactic strains were routinely grown in TYP medium (Bacto-tryptone 16 g/L,
16 g/L Yeast extract, 10 g/L NaCl) and Marine Broth (MB) at 21 ˝C. To allow bacterial growth on solid
media, 17 g/L of bacteriological agar were added to each medium.
Mar. Drugs 2016, 14, 83 10 of 14
3.3. RAPD Analysis
Typing of bacterial isolates was performed using the Random Amplified Polymorphic DNA
(RAPD) technique performed on cell lysates [33–35]; to this purpose, Antarctic bacterial colonies grown
overnight at 21 ˝C on MA plates were suspended in 25 µL of sterile distilled water, heated to 95 ˝C
for 10 min, and cooled on ice for 5 min. RAPD analysis was carried out in a total volume of 25 µL
containing 1ˆ Reaction Buffer, 300 µM MgCl2, 200 µM of each deoxynucleoside triphosphate, 0.5 U of
Polytaq DNA polymerase (Polymed, Florence, Italy), 10 µM of primer 1253 (51GTTTCCGCCC31) or
primer AP5 (51TCACGCTGCG31) and 2 µL of lysate cell suspension [35]. PCR were performed using
MasterCycle Personal Thermal Cycler (Eppendorf, Hamburg, Germany). After incubation at 90 ˝C
for 1 min and 95 ˝C for 1.5 min, the reaction mixtures were cycled 45 times through the following
temperature profile: 95 ˝C for 30 s, 36 ˝C for 1 min, and 75 ˝C for 1 min. Samples were then incubated
at 60 ˝C for 10 min, and finally at 5 ˝C for 10 min. Amplification products were then stored at ´20 ˝C.
Reaction products were analyzed by agarose (2.5 % w/v) gel electrophoresis in TAE buffer containing
0.5 µg/mL (w/v) of ethidium bromide.
3.4. Phylogenetic Affiliation of BTN Strains
Two µL of each cell lysate were used for the amplification via PCR of 16S rRNA genes. PCR
was carried out in a total volume of 50 µL containing 1X Reaction Buffer, 150 µM MgCl2, 250 µM of
each deoxynucleoside triphosphate, and 2.0 U of Polytaq DNA polymerase and 0.6 µM of primer P0
(51GAGAGTTTGATCCTGGCTCAG31) and P6 (51CTACGGCTACCTTGTTACGA31) [36]. The reaction
conditions used were: one cycle (95 ˝C for 90 s), 30 cycles (95 ˝C 30 s, 50 ˝C 30 s, and 72 ˝C 1 min),
with a final extension of 10 min at 72 ˝C. Amplicons corresponding to the 16S rRNA genes (observed
under UV light, 312 nm) were excised from the gel and purified using the “QIAquick” gel extraction
kit (QIAGEN, Chatsworth, CA, USA) according to manufacturer’s instructions. Direct sequencing
was performed on both DNA strands using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems,
Forster City, CA, USA) and the chemical dye terminator [37]. Each 16S rRNA gene sequence was
submitted to GenBank and assigned the accession number shown in Table 1. BLAST probing of DNA
databases was performed with the BLASTn option of the BLAST program using default parameters [38].
Nucleotide sequences were retrieved from RDP databases. The ClustalW program was used to align the
16S rRNA gene sequences obtained with the most similar ones retrieved from the databases [39]. Each
alignment was checked manually, corrected, and then analyzed. The evolutionary history was inferred
using the Neighbor-Joining method according to the model of Kimura two-parameter distances [40,41].
The percentage of replicate trees where the associated taxa clustered together in the bootstrap test
(1000 replicates) is shown next to the branches [42].
3.5. Cross-Streaking
Cross-streaking experiments were carried out as previously described [11]. Petri dishes with or
without a septum separating two hemi-cycles were used. Plates with a central septum allowed the
growth of tester and target strains without any physical contact. Antarctic strains (tester strains) were
grown on MA for four days at 21 ˝C; then, they were streaked on TYP and incubated at 21 ˝C for four
days. Bcc strains (target strains) were perpendicularly streaked to the initial streak and plates were
further incubated at 21 ˝C for two days and at 37 ˝C for two additional days. The experiments were
conducted in parallel with a positive control to verify the viability of Bcc cells.
3.6. Extract Preparation
A single colony of a bacterial isolate was used to inoculate 3 mL of liquid TYP media in sterile
bacteriological tubes. After 48 h of incubation at 21 ˝C at 200 rpm, the pre-inoculum was used to
inoculate 100 mL of TYP medium in a 500 mL flask, at an initial cell concentration of 0.01 OD600/mL.
The flasks were incubated up to five days at 21 ˝C at 200 rpm. The cultures were then centrifuged
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at 6800ˆ g at 4 ˝C for 30’, and the exhausted culture broths were collected and stored at ´20 ˝C.
The exhausted culture broths were subjected to organic extraction using three volumes of ethyl acetate
in a 500 mL separatory funnel. The organic phase collected was evaporated using a Laborota 4000
rotary evaporator (Heidolph, Schwabach, Germany), and the extracts were weight, dissolved in 100%
DMSO at 50 or 100 mg/mL and stored at ´20 ˝C.
3.7. Antimicrobial Assays
3.7.1. Minimal Inhibitory Concentration Assay (MIC)
To evaluate the antimicrobial potential of Antarctic extracts, samples were placed into each well
of a 96-well microtiter plate at an initial concentration of 2% (v/v) and serially diluted using LB
medium. Wells containing no compound represented the negative control. DMSO was used as control
to determine the effect of solvent on cell growth. A single colony of a Bcc strain was used to inoculate
3 mL of liquid LB media in sterile bacteriological tube. After 6–8 h of incubation, growth was measured
by monitoring the absorbance at 600 nm and about 40,000 CFU were dispensed in each well of the
prepared plate. Plates were incubated at 37 ˝C for 24 h and growth was measured with a Cytation3
Plate Reader (Biotek, Winoosky, VT, USA) by monitoring the absorbance at 600 nm.
3.7.2. Minimal Bactericidal Concentration (MBC) Assay
To determine the MBC, the dilution representing the MIC and two of the more concentrated
test product dilutions were plated on LB agar plates and enumerated to determine CFU/mL.
An aliquot of the positive control was plated and used to establish a baseline concentration of the
microorganism used.
3.8. Purification of Ethyl-Acetate Crude Extract
Crude extract of 3 L BTN1 fermentation, prepared as described above, was subjected to
fractionation using Chromabond SPE C18 column cartridges (Macherey-Nagel, Duren, Germany).
HPLC separations were carried out using a VP 250/10 Nucleodur C18 HTec, 5 µm, (Macherey-Nagel
Duren, Germany) connected to a Ultimate 3000 HPLC Chromatograph with a Ultimate 3000 Diode
Array detector and in-line degasser (Dionex, Sunnyvale, CA, USA). Detection was achieved on-line
through a scan of wavelengths from 200 to 400 nm. This process yielded 4.8 mg of 1, 5.3 mg of 2 and
5.7 mg of 3.
Compound 2. [α]D ´53.4˝ (c 0.001 MeOH; UV(MeOH) λmax (log ε) 202 (3.55) nm; IR (film) υmax 3361,
2925, 2855, 1735, 1671, 1575, 1455, 1380, 1314, 1207, 1161, 1126, 1037, 983, cm´1; 1H, 13C, HMBC NMR
data see Table 1; HRESIMS m/z 553.3343 ∆ ´0.75 ppm [M + Na]+ calculated for C28H50O9.
Compound 3. [α]D +49.3˝ (c 0.001 MeOH UV(MeOH) λmax (log ε) 202 (3.78) nm; IR (film) υmax 3387,
2926, 2855, 1667, 1587, 1402, 1316, 1204, 1130, 1072, 1049, 983 cm´1; 1H, 13C, HMBC NMR data see
Table 1; HRESIMS m/z 581.3649 ∆ 1.72 ppm [M + Na]+ calculated for C30H54O9.
3.9. NMR–LCMS Experiments
NMR data, both 1D and 2D were recorded on a spectrometer (Bruker, Billerica, MA, USA) at 600
and 150 MHz for 1H and 13C, respectively, using an ID cryoprobe in methanol-d4 as solvent. Chemical
shifts are reported in parts per million (δ/ppm) downfield relative to residual CD3OD at 3.31 ppm
for protons and 49.0 ppm for carbons. High-resolution mass spectrometry and fragmentation data
were recorded using an LTQ Orbitrap system (ThermoScientific, Whaltman, MA, USA) coupled to
an 1290 Infinity HPLC system (Agilent, Santa Clara, CA, USA). The following conditions were used:
capillary voltage 45 V, capillary temperature 320 ˝C, auxiliary gas flow rate 10–20 arbitrary units,
sheath gas flow rate 40–50 arbitrary units, spray voltage 4.5 kV, mass range 100–2000 amu (maximum
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resolution 30,000). Optical rotation measurements were recorded using a Perkin Elmer, Model 343
Polarimeter at 589 nm (Perkin Elmer, Whaltman, MA, USA). The UV spectrum was recorded on a
UV-Vis spectrophotometer model S10 (Spectromlab, Barcelona, Spain). The IR was recorded on a
PerkinElmer FTIR Spectrum Two instrument (Perkin Elmer, Whaltman, MA, USA).
4. Conclusions
Exploiting a bioassay-driven purification approach, three RLs (one of which was novel) with
antimicrobial activity against Bcc strains, were isolated from Pseudomonas sp. BTN1, recovered
from Antarctic sediments. RLs represent a promising class of biosurfactants as antimicrobials or in
combination with antibiotics. A recent study suggested the use of RLs as an additive in the formulation
of antibiotic and other antimicrobial agents for enhancing the effectiveness of chemotherapeutics [43].
Moreover, the possibility of RL production by the fermentation of organic waste (such us waste oils),
makes these products economically appealing [44]. To the best of our knowledge, this is the first
report of antimicrobial activity of RLs against Bcc strains, and it prompts future studies aimed at RL
exploitation as drugs to counteract these hazardous opportunistic human pathogens.
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